Caloric restriction and Alzheimers ABeta clearance pathway

热量限制和阿尔茨海默病 Aβ 清除途径

基本信息

  • 批准号:
    8411069
  • 负责人:
  • 金额:
    $ 7.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-08-15 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

This research will be done primarily in Serbia at the Institute for Biological Research University of Belgrade (LMIC site) in collaboration with Selma Kanazir with the companion grant being R37AG023084, 9/15/2004 to 8/31/2014. We propose to extend aim 4 of the companion grant to study the effects of caloric dietary restriction (DR) on brain and systemic clearance of Alzheimer's disease (AD) neurotoxin amyloid ¿-peptide (A¿) and on cognitive functions using a transgenic model of AD-like cerebral ¿-amyloidosis. The proposed research will significantly enhance the neuroscience research capacity at the LMIC site which is a major biomedical research institution in Serbia and the capabilities of both the LMIC collaborator and the next generation of Serbian researchers to study brain disorders. The LMIC site has experience in DR models. DR reduces A¿ pathology and improves behavior in mice with AD-like cerebral pathology, but the molecular and cellular mechanisms of this improvement remain elusive. The major goal of this proposal is to determine the effects of DR on (i) brain and systemic A¿ clearance mediated by the sterol response element binding protein 2 (SREBP2)/low density lipoprotein receptor related protein 1 (LRP1) and (ii) cognitive functions. LRP1-mediated A¿ clearance in the cerebrovascular system, blood and liver is the major mechanism for removal of A¿ toxin. SREBP2, a key gene regulating cholesterol metabolism, is a major transcriptional suppressor of LRP1. DR or 24 h fasting downregulates SREBP2 in the liver and brain and increases LRP1 expression as shown by Kanazir's pilot data. Our central hypothesis is that DR downregulates SREBP2 in brain vasculature and liver which in turn increases LRP1 activity promoting brain and systemic A¿ clearance thereby improving cognitive functions. We will study APPsw/0 mice on normal diet or DR (aim 1) and with forced SREBP2 expression induced by myocardin gene transfer to brain blood vessels (aim 2). APPsw/0 mice have been transferred to Belgrade in Nov 2010 to allow Kanazir to start her own colony. This is the first transgenic colony established at the Belgrade University. Members of the Kanazir group are versed with the proposed methods to be performed at the LMIC site and will continue to be trained by Zlokovic's group in new state-of-the art methods as needed. Prior to the FIRCA proposal, Zlokovic visited Kanazir and members of her team in Belgrade during January and June 2010, and Kanazir spent 4 months in Zlokovic's former lab in Rochester from Aug 4 to Dec 7, 2010. Kanazir provided creative and important scientific input to the research plan of the FIRCA. This proposal will contribute to building much needed research capacity at the University of Belgrade by enabling the LMIC site to expand research in brain disorders, to introduce new technological approaches, and develop existing research facilities. It will enable short exchange visits of junior researchers between Belgrade and Los Angeles and help improve the productivity and build enthusiasm among young Serbian researchers. We expect the proposal will establish a long-standing collaboration between the Zlokovic group and the LMIC site/PI's group.
这项研究将主要在塞尔维亚贝尔格莱德大学生物研究所进行

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Berislav V Zlokovic其他文献

RETRACTED ARTICLE: Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C
撤回文章:组织型纤溶酶原激活剂的神经血管毒性由活化蛋白 C 控制
  • DOI:
    10.1038/nm1122
  • 发表时间:
    2004-10-31
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Dong Liu;Tong Cheng;Huang Guo;José A Fernández;John H Griffin;Xiaomei Song;Berislav V Zlokovic
  • 通讯作者:
    Berislav V Zlokovic
RETRACTED ARTICLE: Pericyte degeneration causes white matter dysfunction in the mouse central nervous system
撤回文章:周细胞变性导致小鼠中枢神经系统白质功能障碍
  • DOI:
    10.1038/nm.4482
  • 发表时间:
    2018-02-05
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Axel Montagne;Angeliki M Nikolakopoulou;Zhen Zhao;Abhay P Sagare;Gabriel Si;Divna Lazic;Samuel R Barnes;Madelaine Daianu;Anita Ramanathan;Ariel Go;Erica J Lawson;Yaoming Wang;William J Mack;Paul M Thompson;Julie A Schneider;Jobin Varkey;Ralf Langen;Eric Mullins;Russell E Jacobs;Berislav V Zlokovic
  • 通讯作者:
    Berislav V Zlokovic

Berislav V Zlokovic的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Berislav V Zlokovic', 18)}}的其他基金

PICALM: Role in the pathogenesis and treatment of Alzheimer vascular blood-brain barrier clearance dysfunction, neuronal dysfunction, and amyloid-beta, tau and neurodegenerative disorders
PICALM:在阿尔茨海默病血管血脑屏障清除功能障碍、神经元功能障碍以及 β 淀粉样蛋白、tau 蛋白和神经退行性疾病的发病机制和治疗中的作用
  • 批准号:
    10420229
  • 财政年份:
    2022
  • 资助金额:
    $ 7.56万
  • 项目类别:
Activated protein C mechanisms of brain white matter protection and new therapies for brain white matter ischemic injury
激活蛋白C脑白质保护机制及脑白质缺血性损伤新疗法
  • 批准号:
    10208987
  • 财政年份:
    2020
  • 资助金额:
    $ 7.56万
  • 项目类别:
Biomarker Core
生物标志物核心
  • 批准号:
    10247459
  • 财政年份:
    2020
  • 资助金额:
    $ 7.56万
  • 项目类别:
Biomarker Core
生物标志物核心
  • 批准号:
    9922632
  • 财政年份:
    2020
  • 资助金额:
    $ 7.56万
  • 项目类别:
Activated protein C mechanisms of brain white matter protection and new therapies for brain white matter ischemic injury
激活蛋白C脑白质保护机制及脑白质缺血性损伤新疗法
  • 批准号:
    10029601
  • 财政年份:
    2020
  • 资助金额:
    $ 7.56万
  • 项目类别:
Biomarker Core
生物标志物核心
  • 批准号:
    10655669
  • 财政年份:
    2020
  • 资助金额:
    $ 7.56万
  • 项目类别:
Project 3 - Animal Models Examining Neurovasculature
项目 3 - 检查神经脉管系统的动物模型
  • 批准号:
    10331686
  • 财政年份:
    2016
  • 资助金额:
    $ 7.56万
  • 项目类别:
The role of pericytes in white matter disease
周细胞在白质疾病中的作用
  • 批准号:
    9762993
  • 财政年份:
    2016
  • 资助金额:
    $ 7.56万
  • 项目类别:
Project 3 - Animal Models Examining Neurovasculature
项目 3 - 检查神经脉管系统的动物模型
  • 批准号:
    10621719
  • 财政年份:
    2016
  • 资助金额:
    $ 7.56万
  • 项目类别:
Core B - Biomarkers
核心 B - 生物标志物
  • 批准号:
    10621700
  • 财政年份:
    2016
  • 资助金额:
    $ 7.56万
  • 项目类别:

相似海外基金

ADVANCED GLYCOSYLATION END PRODUCTS AND EFFECT OF MESANGIAL CELLS
高级糖基化最终产物和对系膜细胞的影响
  • 批准号:
    3776700
  • 财政年份:
  • 资助金额:
    $ 7.56万
  • 项目类别:
ADVANCED GLYCOSYLATION END PRODUCTS AND EFFECT OF MESANGIAL CELLS
高级糖基化最终产物和对系膜细胞的影响
  • 批准号:
    3840306
  • 财政年份:
  • 资助金额:
    $ 7.56万
  • 项目类别:
ADVANCED GLYCOSYLATION END PRODUCTS AND EFFECT OF MESANGIAL CELLS
高级糖基化最终产物和对系膜细胞的影响
  • 批准号:
    3855332
  • 财政年份:
  • 资助金额:
    $ 7.56万
  • 项目类别:
GLOMERULAR EFFECTS OF ADVANCED GLYCOSYLATION END PRODUCTS
高级糖基化最终产物对肾小球的影响
  • 批准号:
    5202002
  • 财政年份:
  • 资助金额:
    $ 7.56万
  • 项目类别:
GLOMERULAR EFFECTS OF ADVANCED GLYCOSYLATION END PRODUCTS
高级糖基化最终产物对肾小球的影响
  • 批准号:
    3754540
  • 财政年份:
  • 资助金额:
    $ 7.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了